Abstract
The treatment and prognosis of chronic myeloid leukemia have dramatically changed since the introduction of tyrosine kinase inhibitors, but although several clinical trials have examined their safety with respect to heart function, no data are yet available about the use of these drugs in patients with Brugada syndrome. We report a case of Brugada syndrome diagnosed during tyrosine kinase inhibitor therapy in a 69-year-old Caucasian male with meningioma and chronic myeloid leukemia. This case report highlights the importance of an integrated approach among hematologists and cardiologists to ensure appropriate treatment with tyrosine kinase inhibitors in patients affected by chronic myeloid leukemia who also suffer from Brugada syndrome.
This is a preview of subscription content, log in via an institution to check access.
References
Miyasaka Y, Tsuji H, Yamada K, Tokunaga S, Saito D, Imuro Y, et al. Prevalence and mortality of the Brugada-type electrocardiogram in one city in Japan. J Am Coll Cardiol. 2001;38:771–4.
Antzelevitch C, Brugada P, Porggrefe M, Brugada J, Brugada R, Corrado D, et al. Brugada syndrome: report of the second consensus conference: endorsed by the heart rhythm society and the European heart rhythm association. Circulation. 2005;111:659–70.
Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172–87.
Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 2009;48:964–70.
Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12:908–16.
Tiribelli M, Colatutto A, Marin L, Barbina G, Qualizza U, Damiani D, et al. Brain natriuretic peptide level as marker of cardiac function in imatinib-treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy. Am J Hematol. 2008;83:517–8.
Park YH, Park HJ, Kim BS, Ha E, Jung KH, Yoon SH, et al. BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett. 2006;243:16–22.
Hatfield A, Owen S, Pilot PR. In reply to “Cardiotoxicity of the cancer therapeutic agent imatinib mesylate”. Nat Med. 2007;13:13.
Gambacorti-Passerini C, Tornaghi L, Franceschino A, Piazza R, Corneo G, Pogliani E. In reply to cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2007;13:13–4.
Rosti G, Martinelli G, Baccarani M. In reply to ‘cardiotoxicity of the cancer therapeutic agent imatinib mesylate’. Nat Med. 2007;13:15.
Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110:1233–7.
Verweij J, Casali PG, Kotasek D, Le Cesne A, Reichard P, Judson IR, et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Can. 2007;43:974–8.
Khoury HJ, Guilhot F, Hughes TP, Kim DW, Cortes JE. Dasatinib treatment for Philadelphia chromosome-positive leukemias. Cancer. 2009;115:1381–94.
Bristol-Myers Squibb. SPRYCEL® prescribing information (US). Princeton, NJ: Bristol-Myers Squibb; 2007.
Bristol-Myers Squibb. SPRYCEL® summary of product characteristics (EU). Uxbridge, United Kingdom; 2007.
Talpaz M, Shah N, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531–41.
Acknowledgments
The authors thank Ms. MVC Pragnell, B.A. for language revision of the manuscript. The financial support of the Associazione Italiana contro le Leucemie, Linfomi e Mieloma (AIL)-BARI is gratefully acknowledged.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Sgherza, N., Russo Rossi, A.V., Colonna, P. et al. Use of tyrosine kinase inhibitors in a patient with Brugada syndrome and chronic myeloid leukemia. Int J Hematol 98, 483–486 (2013). https://doi.org/10.1007/s12185-013-1395-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-013-1395-8